In Response
- PMID: 33035038
- PMCID: PMC7288781
- DOI: 10.1213/ANE.0000000000005047
In Response
Conflict of interest statement
Conflicts of Interest: J.H.C. serves on the Speaker’s Bureau for La Jolla Pharmaceutical Company.
Comment on
-
Angiotensin II for the Treatment of COVID-19-Related Vasodilatory Shock.Anesth Analg. 2020 Jul;131(1):102-105. doi: 10.1213/ANE.0000000000004825. Anesth Analg. 2020. PMID: 32209811 Free PMC article. No abstract available.
-
Is Angiotensin II Unopposed a Good Thing?Anesth Analg. 2020 Sep;131(3):e170-e171. doi: 10.1213/ANE.0000000000005046. Anesth Analg. 2020. PMID: 32502133 Free PMC article. No abstract available.
Similar articles
-
Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?Crit Care. 2020 Jul 9;24(1):407. doi: 10.1186/s13054-020-03144-6. Crit Care. 2020. PMID: 32646518 Free PMC article. No abstract available.
-
Why the Use of Angiotensin II May be a Fatal Mistake in COVID-19.Shock. 2020 Nov;54(5):697-699. doi: 10.1097/SHK.0000000000001577. Shock. 2020. PMID: 32453250 Free PMC article. No abstract available.
-
Treatment with angiotensin II in COVID-19 patients may not be beneficial.Crit Care. 2020 Sep 4;24(1):546. doi: 10.1186/s13054-020-03233-6. Crit Care. 2020. PMID: 32887650 Free PMC article. No abstract available.
-
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.Hypertens Res. 2020 Jul;43(7):648-654. doi: 10.1038/s41440-020-0455-8. Epub 2020 Apr 27. Hypertens Res. 2020. PMID: 32341442 Free PMC article. Review.
-
Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.Semin Thromb Hemost. 2020 Oct;46(7):835-837. doi: 10.1055/s-0040-1712960. Epub 2020 Jun 11. Semin Thromb Hemost. 2020. PMID: 32526773 Free PMC article. Review. No abstract available.
References
-
- Tumlin JA, Murugan R, Deane AM, et al. ; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46:949–957. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical